TrialJournal of bone and mineral metabolism2014

Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.

Tetsuo Nakano et al.PubMed ↗Publisher ↗

No numbers read from the abstract.